ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,227.65
0.59%
Dow Jones
39,164.06
0.09%
Gold vs US Dollar
2,335.87
0.35%
Brent Oil
85.815
0.47%
Bitcoin
61,392.38
-0.35%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. NewAmsterdam Pharma Company NV (NAMS)

  7. NewAmsterdam Pharma Company NV (NAMS) News

NewAmsterdam Pharma Comp... (NAMS)

NewAmsterdam Pharma Company NV
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NAMS
DateTimeSourceHeadlineSymbolCompany
11/06/202413:00GlobeNewswire Inc.NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark OfficeNASDAQ:NAMSNewAmsterdam Pharma Company NV
07/06/202421:01GlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSNewAmsterdam Pharma Company NV
29/05/202413:00GlobeNewswire Inc.NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in JuneNASDAQ:NAMSNewAmsterdam Pharma Company NV
21/05/202413:00GlobeNewswire Inc.NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical MeetingsNASDAQ:NAMSNewAmsterdam Pharma Company NV
09/05/202413:00GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsNASDAQ:NAMSNewAmsterdam Pharma Company NV
03/05/202421:01GlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSNewAmsterdam Pharma Company NV
02/05/202413:00GlobeNewswire Inc.NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024NASDAQ:NAMSNewAmsterdam Pharma Company NV
09/04/202413:00GlobeNewswire Inc.NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular DiseaseNASDAQ:NAMSNewAmsterdam Pharma Company NV
01/04/202413:00GlobeNewswire Inc.NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business OfficerNASDAQ:NAMSNewAmsterdam Pharma Company NV
25/03/202412:00GlobeNewswire Inc.NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology CongressNASDAQ:NAMSNewAmsterdam Pharma Company NV
12/03/202412:00GlobeNewswire Inc.NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVDNASDAQ:NAMSNewAmsterdam Pharma Company NV
28/02/202413:00GlobeNewswire Inc.NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:NAMSNewAmsterdam Pharma Company NV
26/02/202413:00GlobeNewswire Inc.NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in MarchNASDAQ:NAMSNewAmsterdam Pharma Company NV
14/02/202403:40GlobeNewswire Inc.NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSNewAmsterdam Pharma Company NV
13/02/202421:01GlobeNewswire Inc.NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSNewAmsterdam Pharma Company NV
01/02/202421:01GlobeNewswire Inc.NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:NAMSNewAmsterdam Pharma Company NV
08/01/202413:00GlobeNewswire Inc.NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of DirectorsNASDAQ:NAMSNewAmsterdam Pharma Company NV
04/01/202413:00GlobeNewswire Inc.NewAmsterdam Pharma Announces 2024 Strategic PrioritiesNASDAQ:NAMSNewAmsterdam Pharma Company NV
13/11/202313:00GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial HighlightsNASDAQ:NAMSNewAmsterdam Pharma Company NV
23/10/202313:00GlobeNewswire Inc.NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial OfficerNASDAQ:NAMSNewAmsterdam Pharma Company NV
21/09/202312:00GlobeNewswire Inc.NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 MutationNASDAQ:NAMSNewAmsterdam Pharma Company NV
20/09/202313:00GlobeNewswire Inc.NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:NAMSNewAmsterdam Pharma Company NV
14/08/202321:01GlobeNewswire Inc.NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial OfficerNASDAQ:NAMSNewAmsterdam Pharma Company NV
07/08/202312:15GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial HighlightsNASDAQ:NAMSNewAmsterdam Pharma Company NV
25/07/202321:01GlobeNewswire Inc.NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular DiseaseNASDAQ:NAMSNewAmsterdam Pharma Company NV
09/06/202321:01GlobeNewswire Inc.NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary SharesNASDAQ:NAMSNewAmsterdam Pharma Company NV
07/06/202304:25GlobeNewswire Inc.NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary SharesNASDAQ:NAMSNewAmsterdam Pharma Company NV
06/06/202321:01GlobeNewswire Inc.NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary SharesNASDAQ:NAMSNewAmsterdam Pharma Company NV
05/06/202312:00GlobeNewswire Inc.NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese PatientsNASDAQ:NAMSNewAmsterdam Pharma Company NV
03/06/202317:15GlobeNewswire Inc.NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023NASDAQ:NAMSNewAmsterdam Pharma Company NV
 Showing the most relevant articles for your search:NASDAQ:NAMS

Your Recent History

BIT
REY
Reply
BIT
1CVS
CVS Health
BIT
P20LS0
NLBNPIT20LS0 20240621 33...
NASDAQ
OTLK
Outlook Therapeutics
BIT
NSCIT5380976
Magnolia
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved